The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression

Advanced gastric cancer is one of the most aggressive gastrointestinal malignancies, and ADAM (A disintegrin and metalloproteinase)-9 is a cell-surface membrane glycoprotein with oncogenic properties that is overexpressed in several cancers. Herein, we investigated the biologic mechanism of ADAM9 in the progression, proliferation, and invasion of gastric cancer. First, we detected ADAM's expression, processing, and protease activity in gastric cancer cells. Protease activity was moderately correlated with ADAM9 protein expression, but was better related to a processed smaller molecular weight (84 kDa) form of ADAM9. Knockdown of ADAM9 or specifically targeted monoclonal antibody (RAV-18) suppressed cancer cell proliferation and invasion in high ADAM9-expressing cells, not in low ADAM9-expressing cells. RAV-18 showed in vivo antitumor activity in a gastric cancer xenograft model. Hypoxia (1% oxygen) induced ADAM9 expression and functional activity in low ADAM9-expressing gastric cancer cells that was inhibited by siRNA knockdown or RAV-18 antibody to levels in normoxic cells. Overall, our studies show that ADAM9 plays an important role in gastric cancer proliferation and invasion, and that while expressed in some gastric cancer cells at high levels that are responsive to functional inhibition and antitumor activity of a catalytic site–directed antibody, other gastric cancer cells have low levels of expression and only when exposed to hypoxia do ADAM9 levels increase and the cells become responsive to ADAM9 antibody inhibition. Therefore, our findings suggest that ADAM9 could be an effective therapeutic target for advanced gastric cancer. Mol Cancer Ther; 13(12); 3074–85. ©2014 AACR.

[1]  H. Kim,et al.  Preclinical Efficacy Testing for Stomach and Liver Cancers , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[2]  Zhong-sheng Zhao,et al.  Upregulated Expression of ADAM17 Is a Prognostic Marker for Patients With Gastric Cancer , 2012, Annals of surgery.

[3]  Jun Sun,et al.  ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway. , 2012, Oncology reports.

[4]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[5]  T. Cotechini,et al.  Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. , 2011, Cancer research.

[6]  Maeve Mullooly,et al.  The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? , 2011, Clinical Proteomics.

[7]  G. Gimpl,et al.  Unsaturated Fatty Acids Drive Disintegrin and Metalloproteinase (ADAM)-dependent Cell Adhesion, Proliferation, and Migration by Modulating Membrane Fluidity* , 2011, The Journal of Biological Chemistry.

[8]  D. Edwards,et al.  The ADAM metalloproteinases , 2008, Molecular Aspects of Medicine.

[9]  M. Alessi,et al.  Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. , 2007, The American journal of pathology.

[10]  D. Stupack.  The biology of integrins. , 2007, Oncology.

[11]  L. Chung,et al.  Reactive oxygen species mediate androgen receptor‐ and serum starvation‐elicited downstream signaling of ADAM9 expression in human prostate cancer cells , 2007, The Prostate.

[12]  Kenoki Ohuchida,et al.  Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. , 2007, Anticancer research.

[13]  F. Marshall,et al.  Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. , 2006, Cancer research.

[14]  F. Checler,et al.  Design and characterization of a novel cellular prion-derived quenched fluorimetric substrate of α-secretase , 2006 .

[15]  Y. Doki,et al.  Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. , 2005, Experimental cell research.

[16]  A. Ullrich,et al.  Oxidative and Osmotic Stress Signaling in Tumor Cells Is Mediated by ADAM Proteases and Heparin-Binding Epidermal Growth Factor , 2004, Molecular and Cellular Biology.

[17]  C. Pilarsky,et al.  ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma , 2004, British Journal of Cancer.

[18]  A. Ullrich,et al.  Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion , 2004, Oncogene.

[19]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[20]  G. Weskamp,et al.  Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity* , 1999, The Journal of Biological Chemistry.

[21]  E. Mekada,et al.  A metalloprotease–disintegrin, MDC9/meltrin‐γ/ADAM9 and PKCδ are involved in TPA‐induced ectodomain shedding of membrane‐anchored heparin‐binding EGF‐like growth factor , 1998, The EMBO journal.

[22]  Nicolson Gl.  Tumor and host molecules important in the organ preference of metastasis. , 1991 .

[23]  F. Checler,et al.  Design and characterization of a novel cellular prion-derived quenched fluorimetric substrate of alpha-secretase. , 2006, Biochemical and biophysical research communications.

[24]  A. Roessner,et al.  The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. , 2005, International journal of oncology.

[25]  C. Röcken,et al.  Increased expression of ADAM family members in human breast cancer and breast cancer cell lines , 2004, Journal of Cancer Research and Clinical Oncology.

[26]  C. Blobel,et al.  Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). , 2003, Current topics in developmental biology.

[27]  Y. Matsuzawa,et al.  Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. , 1999, Gastroenterology.

[28]  S. Albelda,et al.  Role of integrins and other cell adhesion molecules in tumor progression and metastasis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[29]  G. Nicolson.  Tumor and host molecules important in the organ preference of metastasis. , 1991, Seminars in cancer biology.

[30]  Hu Shih,et al.  Development of Methodology , 1980 .

[31]  E. Ludolphy.  [Cancer cells]. , 1950, Medizinische Monatsschrift.